Improved Infusion: A New Device Aimed at Revolutionizing the Way Biologic Infusions are are Administered

Delivering biologics through IV is costly and slow, but not every drug can be delivered subcutaneously. Consumables such as saline bags and IV lines are expensive and take time to set up while CSTD's pose compatibility challenges with pharma products. At Roche, our business priorities include offering medical advances at a reduced cost to society, improving patient access, and ensuring sustainability. This topic will introduce a new device that addresses challenges with IV delivery and enables a different modality of IV administration aligned with our business priorities.

Geoff Wise, Senior Manager Device Development, Genentech